Highlight
– The FDA has approved lonapegsomatropin-tcgd (Skytrofa) for adults with growth hormone deficiency (GHD), expanding its original pediatric indication.
– In the phase 3 foresiGHt trial, once-weekly lonapegsomatropin was superior to placebo and comparable to daily somatropin in improving body composition, with similar safety outcomes.
– Skytrofa’s weekly regimen addresses a significant unmet need for treatment convenience and may enhance adherence among adult GHD patients.
– The approval is expected to influence clinical practice and prompt updates to adult GHD management guidelines.